Kairos Pharma (KAPA) Change in Accured Expenses (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Change in Accured Expenses came in at -$129000.0 in Q2 2025, down 637.5% YoY from $24000.0 in Q2 2024, and up 31.02% on a QoQ basis from -$187000.0 in Q1 2025.
Kairos Pharma (KAPA) Change in Accured Expenses (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Change in Accured Expenses data on file, last reported at -$129000.0 in Q2 2025.
- Quarterly Change in Accured Expenses fell 637.5% year-over-year to -$129000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$246000.0 (changed N/A YoY) and the FY2025 annual result came in at -$793000.0, down 296.29% from the prior year.
- Change in Accured Expenses rose to -$129000.0 in Q2 2025, from -$187000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $310000.0 in Q1 2024 to a low of -$191000.0 in Q3 2024.
- A 3-year average of $40571.4 and a median of $24000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 33.16% — and 2025, when it plunged 637.5%.
- Tracing KAPA's Change in Accured Expenses over 3 years: stood at $196000.0 in 2023, then jumped by 33.16% to $261000.0 in 2024, then slumped by 149.43% to -$129000.0 in 2025.
- The last three Change in Accured Expenses figures came in at -$129000.0 (Q2 2025), -$187000.0 (Q1 2025), and $261000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -129,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | -187,000.00 |
| Mar 31, 2025 | -187,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Sep 30, 2024 | -191,000.00 |
| Sep 30, 2024 | -191,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 310,000.00 |
| Mar 31, 2024 | 310,000.00 |
| Dec 31, 2023 | 196,000.00 |
| Dec 31, 2023 | 196,000.00 |